New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the publication of a research article in Science. The article titled “In vivo editing of lung stem cells for durable gene correction in mice” describes the ability of Selective Organ Targeting (SORT) lipid nanoparticles (LNPs) to facilitate high levels of persistent gene editing in lun
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks